In yesterday’s Wall Street session, Taysha Gene Therapies Inc (NASDAQ:TSHA) shares traded at $1.27, down -5.22% from the previous session.
TSHA stock price is now -37.15% away from the 50-day moving average and -46.78% away from the 200-day moving average. The market capitalization of the company currently stands at $260.27M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $5, BMO Capital Markets recently initiated with Outperform rating for Taysha Gene Therapies Inc (NASDAQ: TSHA). On April 09, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $9, while ‘Jefferies’ rates the stock as ‘Hold’
In other news, Manning Paul B, 10% Owner bought 1,333,333 shares of the company’s stock on Jun 27 ’24. The stock was bought for $2,999,999 at an average price of $2.25. Upon completion of the transaction, the 10% Owner now directly owns 1,333,333 shares in the company, valued at $1.69 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 17 ’23, 10% Owner Manning Paul B bought 100,000 shares of the business’s stock. A total of $163,000 was incurred on buying the stock at an average price of $1.63. This leaves the insider owning 16,566,667 shares of the company worth $21.04 million. A total of 22.67% of the company’s stock is owned by insiders.
During the past 12 months, Taysha Gene Therapies Inc has had a low of $1.27 and a high of $4.32. As of last week, the company has a debt-to-equity ratio of 0.53, a current ratio of 5.20, and a quick ratio of 5.20. The fifty day moving average price for TSHA is $2.0384 and a two-hundred day moving average price translates $2.387375 for the stock.
The latest earnings results from Taysha Gene Therapies Inc (NASDAQ: TSHA) was released for 2024-06-30. The net profit margin was -888.18% and return on equity was -318.69% for TSHA. The company reported revenue of $1.11 million for the quarter, compared to $2.4 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -53.57 percent.
